Skip to main content

Table 1 Characteristics of subjects in the dataset (N = 193)

From: Methylation of HIN-1, RASSF1A, RIL and CDH13 in breast cancer is associated with clinical characteristics, but only RASSF1A methylation is associated with outcome

 

Frequency (%)

Median

(Min, Max)

Race

   

  White

131 (74.86%)

  

  Non-White

44 (25.14%)

  

Menstrual Status

   

  Pre/Peri

28 (15.56%)

  

  Post

154 (84.44%)

  

Histopathology

   

  IDC

161 (83.42%)

  

  ILC

13 (6.74%)

  

  Medullary

5 (2.59%)

  

  Mucinous/Colloid

6 (3.11%)

  

  Tubular

2 (1.04%)

  

  Infiltrating Papillary

2 (1.04%)

  

  Adenocarcinoma

2 (1.04%)

  

  Carcinoma, NOS

2 (1.04%)

  

Tumor Size

   

  ≤ 2 cm

97 (50.26%)

  

  >2 cm and ≤ 5 cm

96 (49.74%)

  

Stage

   

  Stage I

97 (50.26%)

  

  Stage IIA

96 (49.74%)

  

ER

   

  ER+

141 (73.06%)

  

  ER-

52 (26.94%)

  

PR

   

  PR+

85 (47.49%)

  

  PR-

94 (52.51%)

  

Ploidy

   

  Diploid

80 (41.45%)

  

  Aneuploid

113 (58.55%)

  

S-Phase

   

  Low-Medium (≤10%)

102 (53.13%)

  

  High (> 10%)

90 (46.88%)

  

RIL

 

18.1%

(0, 91.2)

HIN-1

 

13.6%

(0, 98.4)

RASSF1A

 

16.1%

(0, 97.1)

CDH13

 

8.6%

(0, 77.1)

Age

 

62 years

(30, 88)

Median follow-up time*

 

152 months

 
  1. *Determined by scoring deaths as censored events and calculating follow-up time using Cox regression.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us